Phase III
ARCA Biopharma, located in Westminster, Colorado, announced mixed but positive outcomes from a Phase II clinical trial of its beta-blocker Gencaro for atrial fibrillation (AF) patients with heart failure (HF).
Only a matter of days after Roche filed its second-quarter financial report, it’s had plenty of news to report.
RedHill Biopharma, with offices in Tel Aviv, Israel and Raleigh, North Carolina, announced positive topline data from its first Phase III trial of RHB-104 for Crohn’s disease. It met all primary endpoint and key secondary endpoints.
The U.S. Food and Drug Administration (FDA) approved Indivior’s Perseris for schizophrenia.
Liquidia Technologiesnlaunched a successful initial public offering on July 25, raising $50 million. Neal Fowler, the company’s chief executive officer, and Kevin Gordon, Liquidia’s president and chief financial officer, took time out to talk with BioSpace about the company and where it’s headed.
Tonix Pharmaceuticals is halting its Phase III clinical trial of Tonmya in military related posttraumatic stress disorder (PTSD).
Although the overall stock market has been a bit jittery as the result of a trade war, biotech stocks have been surprisingly steady—at least in comparison to their usual volatility.
It’s hard to say if it was actually a wild ride after the release of Alzheimer’s data, but Biogen shares dropped from $383.83 to $340.84 at the news, although it appears to be rebounding slightly.
AstraZeneca’s second-quarter report had a mix of good news and bad news. On the good news side, oncology sales rocketed 37 percent, with strong sales of Lynparza, Tagrisso and Imfinzi. On the bad news side, the company’s selumetinib failed another clinical trial.
Many analysts and investors were holding their breaths, waiting to see what Biogen would say at yesterday’s second-quarter financial report. The financials weren’t the focus, however, but what the Cambridge, Massachusetts biotech had to say about its pipeline, especially for Alzheimer’s disease, was.
PRESS RELEASES